Loading...
Header Logo
Keywords
Last Name
Institution

MICHAEL GILCREASE

TitleProfessor
InstitutionMD Anderson
DepartmentPathology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Guo H, Ding Q, Gong Y, Gilcrease MZ, Zhao M, Zhao J, Sui D, Wu Y, Chen H, Liu H, Zhang J, Resetkova E, Moulder SL, Wang WL, Huo L. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors. Breast Cancer Res. 2020 06 23; 22(1):69. PMID: 32576238.
      View in: PubMed
    2. Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174. PMID: 31005169.
      View in: PubMed
    3. Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SL. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309. PMID: 30139837.
      View in: PubMed
    4. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2018 05; 267(5):946-951. PMID: 28549010.
      View in: PubMed
    5. Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SL. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515. PMID: 27893038.
      View in: PubMed
    6. Dave B, Gonzalez DD, Liu ZB, Li X, Wong H, Granados S, Ezzedine NE, Sieglaff DH, Ensor JE, Miller KD, Radovich M, KarinaEtrovic A, Gross SS, Elemento O, Mills GB, Gilcrease MZ, Chang JC. Role of RPL39 in Metaplastic Breast Cancer. J Natl Cancer Inst. 2017 06; 109(6). PMID: 28040796.
      View in: PubMed
    7. Gilcrease MZ, Dogan BE, Black DM, Contreras A, Dryden MJ, Jimenez SM. Transection of Radioactive Seeds in Breast Specimens. Am J Surg Pathol. 2016 10; 40(10):1375-9. PMID: 27627744.
      View in: PubMed
    8. Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA, Acklin K, Ramirez K, Hafley M, Alt E, Vykoukal J, Bresalier RS. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res. 2016 09 29; 18(1):97. PMID: 27687248.
      View in: PubMed
    9. Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 May 10; 7(19):28329-39. PMID: 27078845.
      View in: PubMed
    10. Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 01; 34(10):1072-8. PMID: 26811528.
      View in: PubMed
    11. Moulder S, Helgason T, Janku F, Wheler J, Moroney J, Booser D, Albarracin C, Morrow PK, Atkins J, Koenig K, Gilcrease M, Kurzrock R. Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Ann Oncol. 2015 Jul; 26(7):1346-52. PMID: 25878190.
      View in: PubMed
    12. Huo L, Gong Y, Guo M, Gilcrease MZ, Wu Y, Zhang H, Zhang J, Resetkova E, Hunt KK, Deavers MT. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology. 2015 Aug; 67(2):245-54. PMID: 25564996.
      View in: PubMed
    13. Eghtedari M, Dogan BE, Gilcrease M, Roberts J, Cook ED, Yang WT. Imaging and pathologic characteristics of breast amyloidosis. Breast J. 2015 Mar-Apr; 21(2):197-9. PMID: 25585499.
      View in: PubMed
    14. Lawton TJ, Acs G, Argani P, Farshid G, Gilcrease M, Goldstein N, Koerner F, Rowe JJ, Sanders M, Shah SS, Reynolds C. Interobserver variability by pathologists in the distinction between cellular fibroadenomas and phyllodes tumors. Int J Surg Pathol. 2014 Dec; 22(8):695-8. PMID: 25161205.
      View in: PubMed
    15. Dave B, Granados-Principal S, Zhu R, Benz S, Rabizadeh S, Soon-Shiong P, Yu KD, Shao Z, Li X, Gilcrease M, Lai Z, Chen Y, Huang TH, Shen H, Liu X, Ferrari M, Zhan M, Wong ST, Kumaraswami M, Mittal V, Chen X, Gross SS, Chang JC. Targeting RPL39 and MLF2 reduces tumor initiation and metastasis in breast cancer by inhibiting nitric oxide synthase signaling. Proc Natl Acad Sci U S A. 2014 Jun 17; 111(24):8838-43. PMID: 24876273.
      View in: PubMed
    16. Nayak A, Carkaci S, Gilcrease MZ, Liu P, Middleton LP, Bassett RL, Zhang J, Zhang H, Coyne RL, Bevers TB, Sneige N, Huo L. Benign papillomas without atypia diagnosed on core needle biopsy: experience from a single institution and proposed criteria for excision. Clin Breast Cancer. 2013 Dec; 13(6):439-49. PMID: 24119786.
      View in: PubMed
    17. Gilcrease MZ. No benefit to intraoperative assessment of breast margins? Am J Clin Pathol. 2013 Oct; 140(4):597. PMID: 24045560.
      View in: PubMed
    18. Krishnamurthy S, Mathews K, McClure S, Murray M, Gilcrease M, Albarracin C, Spinosa J, Chang B, Ho J, Holt J, Cohen A, Giri D, Garg K, Bassett RL, Liang K. Multi-institutional comparison of whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Arch Pathol Lab Med. 2013 Dec; 137(12):1733-9. PMID: 23947655.
      View in: PubMed
    19. Nayak A, Wu Y, Gilcrease MZ. Primary squamous cell carcinoma of the breast: predictors of locoregional recurrence and overall survival. Am J Surg Pathol. 2013 Jun; 37(6):867-73. PMID: 23629447.
      View in: PubMed
    20. Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H, Resetkova E, Hunt KK, Deavers MT. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology. 2013 Jan; 62(2):267-74. PMID: 22963676.
      View in: PubMed
    21. Duan X, Sneige N, Gullett AE, Prieto VG, Resetkova E, Andino LM, Wu Y, Gilcrease MZ, Bedrosian I, Dawood S, Arun B, Albarracin CT. Invasive paget disease of the breast: clinicopathologic study of an underrecognized entity in the breast. Am J Surg Pathol. 2012 Sep; 36(9):1353-8. PMID: 22895267.
      View in: PubMed
    22. Alvarado R, Yi M, Le-Petross H, Gilcrease M, Mittendorf EA, Bedrosian I, Hwang RF, Caudle AS, Babiera GV, Akins JS, Kuerer HM, Hunt KK. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012 Oct; 19(10):3177-84. PMID: 22772869.
      View in: PubMed
    23. de la Cruz J, Andre F, Harrell RK, Bassett RL, Arun B, Mathieu MC, Delaloge S, Gilcrease MZ. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. Hum Pathol. 2012 Nov; 43(11):1932-9. PMID: 22591913.
      View in: PubMed
    24. Smith TB, Gilcrease MZ, Santiago L, Hunt KK, Yang WT. Imaging features of primary breast sarcoma. AJR Am J Roentgenol. 2012 Apr; 198(4):W386-93. PMID: 22451578.
      View in: PubMed
    25. Perry KD, Reynolds C, Rosen DG, Edgerton ME, T Albarracin C, Gilcrease MZ, Sahin AA, Abraham SC, Wu Y. Metastatic neuroendocrine tumour in the breast: a potential mimic of in-situ and invasive mammary carcinoma. Histopathology. 2011 Oct; 59(4):619-30. PMID: 22014043.
      View in: PubMed
    26. Tang F, Wei B, Tian Z, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Zhang H, Sahin A, Chen J, Bu H, Abraham S, Wu Y. Invasive mammary carcinoma with neuroendocrine differentiation: histological features and diagnostic challenges. Histopathology. 2011 Jul; 59(1):106-15. PMID: 21668471.
      View in: PubMed
    27. Carkaci S, Lane DL, Gilcrease MZ, Conrow D, Schwartz MR, Huynh P, Yang WT. Do all mucocele-like lesions of the breast require surgery? Clin Imaging. 2011 Mar-Apr; 35(2):94-101. PMID: 21377046.
      View in: PubMed
    28. Tian Z, Wei B, Tang F, Wei W, Gilcrease MZ, Huo L, Albarracin CT, Resetkova E, Middleton L, Sahin A, Xing Y, Hunt KK, Chen J, Bu H, Rashid A, Abraham SC, Wu Y. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol. 2011 Aug; 42(8):1169-77. PMID: 21334720.
      View in: PubMed
    29. Lester TR, Hunt KK, Nayeemuddin KM, Bassett RL, Gonzalez-Angulo AM, Feig BW, Huo L, Rourke LL, Davis WG, Valero V, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast appears more aggressive than other triple receptor-negative breast cancers. Breast Cancer Res Treat. 2012 Jan; 131(1):41-8. PMID: 21331622.
      View in: PubMed
    30. Wahbah MM, Gilcrease MZ, Wu Y. Lipomatous variant of myofibroblastoma with epithelioid features: a rare and diagnostically challenging breast lesion. Ann Diagn Pathol. 2011 Dec; 15(6):454-8. PMID: 21036082.
      View in: PubMed
    31. Brown AS, Hunt KK, Shen J, Huo L, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Boughey JC, Ching CD, Gilcrease MZ. Histologic changes associated with false-negative sentinel lymph nodes after preoperative chemotherapy in patients with confirmed lymph node-positive breast cancer before treatment. Cancer. 2010 Jun 15; 116(12):2878-83. PMID: 20564394.
      View in: PubMed
    32. Nguyen CV, Falcón-Escobedo R, Hunt KK, Nayeemuddin KM, Lester TR, Harrell RK, Bassett RL, Gilcrease MZ. Pleomorphic ductal carcinoma of the breast: predictors of decreased overall survival. Am J Surg Pathol. 2010 Apr; 34(4):486-93. PMID: 20154588.
      View in: PubMed
    33. Morkowski JJ, Nguyen CV, Lin P, Farr M, Abraham SC, Gilcrease MZ, Moran CA, Wu Y. Rosai-Dorfman disease confined to the breast. Ann Diagn Pathol. 2010 Apr; 14(2):81-7. PMID: 20227012.
      View in: PubMed
    34. Dogan BE, Gonzalez-Angulo AM, Gilcrease M, Dryden MJ, Yang WT. Multimodality imaging of triple receptor-negative tumors with mammography, ultrasound, and MRI. AJR Am J Roentgenol. 2010 Apr; 194(4):1160-6. PMID: 20308526.
      View in: PubMed
    35. Albarracin C, Edgerton ME, Gilcrease MZ, Huo L, Krishnamurthy S, Middleton LP, Resetkova E, Sahin AA, Sneige N, Fraser WS, Wu Y. Is it too soon to start reporting HER2 genetic heterogeneity? Arch Pathol Lab Med. 2010 Feb; 134(2):162-3; author reply 163. PMID: 20121597.
      View in: PubMed
    36. Diaz LK, Gilcrease MZ. A prospective feasibility trial to determine the significance of the sentinel node gradient in breast cancer: a predictor of nodal metastasis location. Cancer. 2009 Dec 15; 115(24):5845; author reply 5846. PMID: 19806639.
      View in: PubMed
    37. Adrada B, Arribas E, Gilcrease M, Yang WT. Invasive micropapillary carcinoma of the breast: mammographic, sonographic, and MRI features. AJR Am J Roentgenol. 2009 Jul; 193(1):W58-63. PMID: 19542384.
      View in: PubMed
    38. Gilcrease MZ, Zhou X, Lu X, Woodward WA, Hall BE, Morrissey PJ. Alpha6beta4 integrin crosslinking induces EGFR clustering and promotes EGF-mediated Rho activation in breast cancer. J Exp Clin Cancer Res. 2009 May 26; 28:67. PMID: 19470173.
      View in: PubMed
    39. Huo L, Gilcrease MZ. Fibroepithelial lesions of the breast with pleomorphic stromal giant cells: a clinicopathologic study of 4 cases and review of the literature. Ann Diagn Pathol. 2009 Aug; 13(4):226-32. PMID: 19608080.
      View in: PubMed
    40. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009 May 15; 69(10):4116-24. PMID: 19435916.
      View in: PubMed
    41. Gilcrease MZ, Woodward WA, Nicolas MM, Corley LJ, Fuller GN, Esteva FJ, Tucker SL, Buchholz TA. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009 May; 33(5):759-67. PMID: 19252432.
      View in: PubMed
    42. Downs-Kelly E, Nayeemuddin KM, Albarracin C, Wu Y, Hunt KK, Gilcrease MZ. Matrix-producing carcinoma of the breast: an aggressive subtype of metaplastic carcinoma. Am J Surg Pathol. 2009 Apr; 33(4):534-41. PMID: 19047898.
      View in: PubMed
    43. Khalifeh I, Deavers MT, Cristofanilli M, Coleman RL, Malpica A, Gilcrease MZ. Primary peritoneal serous carcinoma presenting as inflammatory breast cancer. Breast J. 2009 Mar-Apr; 15(2):176-81. PMID: 19292804.
      View in: PubMed
    44. Gilcrease MZ, Kilpatrick SK, Woodward WA, Zhou X, Nicolas MM, Corley LJ, Fuller GN, Tucker SL, Diaz LK, Buchholz TA, Frost JA. Coexpression of alpha6beta4 integrin and guanine nucleotide exchange factor Net1 identifies node-positive breast cancer patients at high risk for distant metastasis. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):80-6. PMID: 19124484.
      View in: PubMed
    45. Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008 Jul 01; 113(1):30-7. PMID: 18457326.
      View in: PubMed
    46. Yang WT, Hennessy B, Broglio K, Mills C, Sneige N, Davis WG, Valero V, Hunt KK, Gilcrease MZ. Imaging differences in metaplastic and invasive ductal carcinomas of the breast. AJR Am J Roentgenol. 2007 Dec; 189(6):1288-93. PMID: 18029860.
      View in: PubMed
    47. Hennessy BT, Gilcrease MZ, Kim E, Gonzalez-Angulo AM. Breast carcinoma with neuroendocrine differentiation and myocardial metastases. Clin Breast Cancer. 2007 Dec; 7(11):892-4. PMID: 18269781.
      View in: PubMed
    48. Yang WT, Dryden M, Broglio K, Gilcrease M, Dawood S, Dempsey PJ, Valero V, Hortobagyi G, Atchley D, Arun B. Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women. Breast Cancer Res Treat. 2008 Oct; 111(3):405-10. PMID: 18026834.
      View in: PubMed
    49. Nicolas MM, Wu Y, Middleton LP, Gilcrease MZ. Loss of myoepithelium is variable in solid papillary carcinoma of the breast. Histopathology. 2007 Nov; 51(5):657-65. PMID: 17927587.
      View in: PubMed
    50. Izaddoost S, Boughey JC, Williams SA, Gilcrease M, Ames F. An unusual presentation of locally recurrent breast cancer: a case report. Breast J. 2007 May-Jun; 13(3):294-6. PMID: 17461906.
      View in: PubMed
    51. Mazurek N, Sun YJ, Liu KF, Gilcrease MZ, Schober W, Nangia-Makker P, Raz A, Bresalier RS. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells. J Biol Chem. 2007 Jul 20; 282(29):21337-48. PMID: 17420249.
      View in: PubMed
    52. Shen J, Gilcrease MZ, Babiera GV, Ross MI, Meric-Bernstam F, Feig BW, Kuerer HM, Francis A, Ames FC, Hunt KK. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007 Apr 01; 109(7):1255-63. PMID: 17330229.
      View in: PubMed
    53. Gilcrease MZ. Sarcomatoid breast tumors have sarcomatoid behavior. Am J Surg Pathol. 2007 Feb; 31(2):326-7; author reply 327. PMID: 17255781.
      View in: PubMed
    54. Gilcrease MZ. Integrin signaling in epithelial cells. Cancer Lett. 2007 Mar 08; 247(1):1-25. PMID: 16725254.
      View in: PubMed
    55. Gilcrease MZ, Sahin A. Pathological evaluation of axillary sentinel lymph nodes in breast cancer. Methods Mol Med. 2006; 120:113-25. PMID: 16491598.
      View in: PubMed
    56. Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ. Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer. Am J Surg Pathol. 2005 Nov; 29(11):1456-63. PMID: 16224212.
      View in: PubMed
    57. Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology. 2005 Oct; 237(1):342-7. PMID: 16183941.
      View in: PubMed
    58. Diaz LK, Cristofanilli M, Zhou X, Welch KL, Smith TL, Yang Y, Sneige N, Sahin AA, Gilcrease MZ. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. Mod Pathol. 2005 Sep; 18(9):1165-75. PMID: 15920552.
      View in: PubMed
    59. Gong Y, Gilcrease M, Sneige N. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility. Mod Pathol. 2005 Aug; 18(8):1015-21. PMID: 15861212.
      View in: PubMed
    60. Erguvan-Dogan B, Dempsey PJ, Ayyar G, Gilcrease MZ. Primary desmoid tumor (extraabdominal fibromatosis) of the breast. AJR Am J Roentgenol. 2005 Aug; 185(2):488-9. PMID: 16037525.
      View in: PubMed
    61. Diaz LK, Zhou X, Wright ET, Cristofanilli M, Smith T, Yang Y, Sneige N, Sahin A, Gilcrease MZ. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin Cancer Res. 2005 May 01; 11(9):3309-14. PMID: 15867228.
      View in: PubMed
    62. Vigneswaran N, Wu J, Sacks P, Gilcrease M, Zacharias W. Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. J Oral Pathol Med. 2005 Feb; 34(2):77-86. PMID: 15641986.
      View in: PubMed
    63. Gilcrease MZ, Zhou X, Welch K. Adhesion-independent alpha6beta4 integrin clustering is mediated by phosphatidylinositol 3-kinase. Cancer Res. 2004 Oct 15; 64(20):7395-8. PMID: 15492261.
      View in: PubMed
    64. Cserni G. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2004 Feb; 28(2):275; author reply 275-6. PMID: 15043322.
      View in: PubMed
    65. Diaz LK, Zhou X, Welch K, Sahin A, Gilcrease MZ. Chromogenic in situ hybridization for alpha6beta4 integrin in breast cancer: correlation with protein expression. J Mol Diagn. 2004 Feb; 6(1):10-5. PMID: 14736821.
      View in: PubMed
    66. Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):136-43. PMID: 14734462.
      View in: PubMed
    67. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res. 2003 Nov 15; 9(15):5652-9. PMID: 14654548.
      View in: PubMed
    68. Diaz LK, Hunt K, Ames F, Meric F, Kuerer H, Babiera G, Ross M, Singletary E, Middleton LP, Symmans WF, Krishnamurthy S, Sahin A, Sneige N, Gilcrease MZ. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9. PMID: 12604895.
      View in: PubMed
    69. Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD, Gazdar AF. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 2003 Jan 10; 103(2):153-60. PMID: 12455028.
      View in: PubMed
    70. Zhang X, Liu Y, Gilcrease MZ, Yuan XH, Clayman GL, Adler-Storthz K, Chen Z. A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer. 2002 Oct 15; 95(8):1663-72. PMID: 12365014.
      View in: PubMed
    71. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001 Nov; 1(1):61-7. PMID: 12467239.
      View in: PubMed
    72. Liu Y, Gilcrease MZ, Henderson Y, Yuan XH, Clayman GL, Chen Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. Cancer Lett. 2001 Aug 28; 169(2):173-80. PMID: 11431106.
      View in: PubMed
    73. Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, Maruyama R, Toyooka KO, Gilcrease M, Farinas A, Minna JD, Gazdar AF. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res. 2001 Aug 01; 61(15):5727-30. PMID: 11479207.
      View in: PubMed
    74. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, Gazdar AF. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res. 2001 Jul; 7(7):1998-2004. PMID: 11448917.
      View in: PubMed
    75. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001 Jun 01; 61(11):4556-60. PMID: 11389090.
      View in: PubMed
    76. Gilcrease MZ, Niehans G. Adhesion of aspirated tumor cells to extracellular matrix proteins: a new methodology utilizing fine-needle aspiration. Cancer. 2000 Apr 25; 90(2):102-10. PMID: 10794159.
      View in: PubMed
    77. Gilcrease MZ, Nelson FS, Guzman-Paz M. Nontyrosine crystalloids? Diagn Cytopathol. 2000 Jan; 22(1):60-1; author reply 62. PMID: 10613976.
      View in: PubMed
    78. Gilcrease MZ, Guzman-Paz M, Niehans G, Cherwitz D, McCarthy JB, Albores-Saavedra J. Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence. Cancer. 1999 Dec 01; 86(11):2320-6. PMID: 10590373.
      View in: PubMed
    79. Nussenbaum B, Roland PS, Gilcrease MZ, Odell DS. Extra-articular synovial chondromatosis of the temporomandibular joint: pitfalls in diagnosis. Arch Otolaryngol Head Neck Surg. 1999 Dec; 125(12):1394-7. PMID: 10604423.
      View in: PubMed
    80. Gilcrease MZ, Delgado R, Albores-Saavedra J. Intrasellar adenoid cystic carcinoma and papillary mucinous adenocarcinoma: two previously undescribed primary neoplasms at this site. Ann Diagn Pathol. 1999 Jun; 3(3):141-7. PMID: 10359849.
      View in: PubMed
    81. Albores-Saavedra J, Gilcrease M. Glomus tumor of the uterine cervix. Int J Gynecol Pathol. 1999 Jan; 18(1):69-72. PMID: 9891244.
      View in: PubMed
    82. Gilcrease MZ, Delgado R, Vuitch F, Albores-Saavedra J. Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison. Hum Pathol. 1998 Dec; 29(12):1451-6. PMID: 9865832.
      View in: PubMed
    83. Gilcrease MZ, Guzman-Paz M, Froberg K, Pambuccian S. Salivary duct carcinoma. Is a specific diagnosis possible by fine needle aspiration cytology? Acta Cytol. 1998 Nov-Dec; 42(6):1389-96. PMID: 9850648.
      View in: PubMed
    84. Gilcrease MZ, Sahin M, Perri RT, Nelson FS, Guzman-Paz M. Fine needle aspiration of signet-ring cell lymphoma. A case report with differential diagnostic considerations. Acta Cytol. 1998 Nov-Dec; 42(6):1461-7. PMID: 9850663.
      View in: PubMed
    85. Gilcrease MZ, Delgado R, Albores-Saavedra J. Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. Arch Pathol Lab Med. 1998 Oct; 122(10):907-11. PMID: 9786352.
      View in: PubMed
    86. Gilcrease MZ, Guzman-Paz M. Fine-needle aspiration of basaloid squamous carcinoma: a case report with review of differential diagnostic considerations. Diagn Cytopathol. 1998 Sep; 19(3):210-5. PMID: 9740998.
      View in: PubMed
    87. Gilcrease MZ, Nelson FS, Guzman-Paz M. Tyrosine-rich crystals associated with oncocytic salivary gland neoplasms. Arch Pathol Lab Med. 1998 Jul; 122(7):644-9. PMID: 9674547.
      View in: PubMed
    88. Gilcrease MZ. Minimal residual cancer. Am J Surg Pathol. 1997 Dec; 21(12):1524-5. PMID: 9414200.
      View in: PubMed
    89. Gilcrease MZ, Rajan B, Ostrowski ML, Ramzy I, Schwartz MR. Localized thymic Langerhans' cell histiocytosis and its relationship with myasthenia gravis. Immunohistochemical, ultrastructural, and cytometric studies. Arch Pathol Lab Med. 1997 Feb; 121(2):134-8. PMID: 9126040.
      View in: PubMed
    90. Gilcrease MZ, Truong L, Brown RW. Correlation of very late activation integrin and CD44 expression with extrarenal invasion and metastasis of renal cell carcinomas. Hum Pathol. 1996 Dec; 27(12):1355-60. PMID: 8958311.
      View in: PubMed
    91. Gilcrease MZ, Schmidt L, Zbar B, Truong L, Rutledge M, Wheeler TM. Somatic von Hippel-Lindau mutation in clear cell papillary cystadenoma of the epididymis. Hum Pathol. 1995 Dec; 26(12):1341-6. PMID: 8522307.
      View in: PubMed
    92. Gilcrease MZ, Brandt ML, Hawkins EP. Yolk sac tumor identified at autopsy after surgical excision of immature sacrococcygeal teratoma. J Pediatr Surg. 1995 Jun; 30(6):875-7. PMID: 7666328.
      View in: PubMed
    93. Gilcrease MZ, Hoover RL. Secretion of a chemotactic substance(s) by AGE-stimulated human monocytes. Diabetes Res Clin Pract. 1992 Apr; 16(1):7-11. PMID: 1576934.
      View in: PubMed
    94. Gilcrease MZ, Hoover RL. Human monocyte interactions with non-enzymatically glycated collagen. Diabetologia. 1992 Feb; 35(2):160-4. PMID: 1547921.
      View in: PubMed
    95. Gilcrease MZ, Hoover RL. Examination of monocyte adherence to endothelium under hyperglycemic conditions. Am J Pathol. 1991 Nov; 139(5):1089-97. PMID: 1835304.
      View in: PubMed
    96. Gilcrease MZ, Hoover RL. Neutrophil adhesion to endothelium following hyperosmolar insult. Diabetes Res. 1991 Apr; 16(4):149-57. PMID: 1802480.
      View in: PubMed
    97. Gilcrease MZ, Hoover RL. Activated human monocytes exhibit receptor-mediated adhesion to a non-enzymatically glycosylated protein substrate. Diabetologia. 1990 Jun; 33(6):329-33. PMID: 2165945.
      View in: PubMed
    98. Decrease in bcl-2 expression shortly after neoadjuvant chemotherapy predicts primary breast cancer response to treatment. Breast Cancer Research and Treatment. 69:244.
    99. A novel morphologic-molecular recurrence predictive model refines traditional prognostic tools for invasive breast carcinoma. Breast Diseases. 26:142-143.
    100. Variability in Gross and Microscopic Pathology Reporting in Excisional Biopsies of Breast Cancer Tissue. Breast Diseases. 17:371.
    101. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Histopathology.
    102. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. Breast Diseases. 21:337-338.
    103. Axillary Sentinel Lymph Nodes Can Be Falsely Positive Due to Iatrogenic Displacement and Transport of Benign Epithelial Cells in Patients With Breast Carcinoma. Breast Diseases. 18:65-66.
    104. Ki-67 as Prognostic Marker in Early Breast Cancer. Breast Diseases. 19:51-52.
    105. Transection of radioactive seeds in breast specimens. American Journal of Surgical Pathology. 40:1375-1379.
    106. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Research. 18.
    107. 1-33 Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer. Breast Diseases. 18:63-64.
    108. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 7:28329-28339.
    109. 4-35 Perpendicular Inked Versus Tangential Shaved Margins in Breast-Conserving Surgery. Breast Diseases. 18:383-384.
    110. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer. Breast Diseases. 27:130-131.
    111. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status. Breast Diseases. 25:93-94.
    112. Carcinosarcoma of the Breast. 257-269.
    113. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Breast Diseases. 23:244-246.
    114. Clinical-pathologic features, long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). Breast Diseases. 24:348-349.
    115. 4-22 The Clinical Significance of Lobular Neoplasia on Breast Core Biopsy. Breast Diseases. 18:368-369.
    116. 3-30 Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Breast Diseases. 18:272-273.
    117. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Breast Diseases. 16:356.
    118. Immunohistochemical and Clinicopathologic Characteristics of Invasive Ductal Carcinoma of Breast With Micropapillary Carcinoma Component. Breast Diseases. 17:154.
    119. In response. American Journal of Surgical Pathology. 33:1739-1740.
    120. On clinically meaningful terminology for sarcomatoid tumors of the breast [2]. American Journal of Surgical Pathology. 30:1053-1055.
    121. Multi-institutional comparison of Whole slide digital imaging and optical microscopy for interpretation of hematoxylin-eosin-stained breast tissue sections. Archives of Pathology and Laboratory Medicine. 137:1733-1739.
    122. Nontyrosine crystalloids? [1] (multiple letters). Diagnostic Cytopathology. 22:60-61.
    123. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Breast Diseases. 21:336-337.
    124. Expression of cell adhesion molecules and prognosis in breast cancer. Breast Diseases. 24:247-248.
    125. Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes. Journal of Clinical Oncology. 34:1072-1078.
    126. 3-19 Papillary Lesions of the Breast at Percutaneous Core-Needle Biopsy. Breast Diseases. 17:240-241.
    127. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Breast Diseases. 24:242-243.
    128. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Breast Diseases. 25:311-312.
    129. How Many Etiological Subtypes of Breast Cancer. Breast Diseases. 26:296-297.
    130. Significance of E-cadherin expression in triple-negative breast cancer. Breast Diseases. 22:54-56.
    131. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Breast Diseases. 24:38-39.
    132. Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. Breast Diseases. 15:156.
    133. Matrix-producing carcinoma. American Journal of Surgical Pathology. 34:125-126.
    134. An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. Breast Diseases. 22:273-274.
    135. Carcinosarcoma of the Breast. 218-229.
    136. Is immunohistochemical analysis of sentinel lymph nodes obsolete?. Breast Diseases. 22:237-238.
    137. HER2 protein and gene variation between primary and metastatic breast cancer. Breast Diseases. 23:157-158.
    138. Does Using a Higher Cutoff for the Percentage of Positive Cells Improve the Specificity of HER-2 Immunohistochemical Analysis in Breast Carcinoma?. Breast Diseases. 19:143-144.
    139. Myofibroblastoma of the breast. European Journal of Radiology Extra. 73.
    140. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. Breast Diseases. 25:237-238.
    141. Selective intraoperative consultation for the evaluation of sentinel lymph nodes in breast cancer. Breast Diseases. 16:158-159.
    142. Prognostic factors in metaplastic carcinoma of the breast. Breast Diseases. 26:221-222.
    143. Prognostic relevance of histological grade and its components in node-negative breast cancer patients. Breast Diseases. 16:49-50.
    GILCREASE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description